Navigation Links
3SBio Inc. To Report 2010 First Quarter Unaudited Financial Results on May 16, 2010
Date:5/11/2010

SHENYANG, China, May 11 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited financial results for the first quarter ended March 31, 2010 on May 16, 2010 at 8:00pm (Eastern).

Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing/Hong Kong) on May 17, 2010 to discuss its 2010 first quarter financial results and recent business activity.

    The conference call may be accessed using the dial-in numbers below:

    Conference ID: 74760426

    Local dial-in:
    China - landline 800 819 0121
    China - mobile 400 620 8038
    Hong Kong - 852 2475 0994

    International toll-free dial-in:
    Hong Kong 800 930 346
    United Kingdom 080 8234 6646
    United States 1 866 519 4004
    International toll dial-in: 65 6723 9381

A telephone replay will be available two hours after the call until May 24, 2010 at:

    International dial-in: +61-2-8235-5000
    United States dial-in: 1-866-214-5335
    Replay- Conference ID: 74760426

Webcast

A live webcast of the conference will be available on the investor relations page of 3SBio's website at http://bbs.3sbio.com/en/News/xinvestors.aspx and at http://tinyurl.com/3sbio2010Q1 . A replay of the webcast will be available within one hour after the conclusion of the call.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3SBio.com

    Investor Contacts

     Bo Tan
     Chief Financial Officer
     3SBio Inc.
     Tel:   +86-24-2581-1820
     Email: ir@3SBio.com

     Tom Folinsbee
     Director of Investor Relations
     3SBio Inc.
     Tel:   +852-8191-6991
     Email: ir@3SBio.com


'/>"/>
SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Announces Changes to its Board of Directors
2. 3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial
3. 3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results
4. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
5. 3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia
6. 3SBio Inc. to Report 2009 Fourth Quarter and Full Year Results on February 11, 2010
7. 3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM)
8. 3SBio Inc. Announces Unaudited Third Quarter 2009 Results
9. 3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009
10. 3SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009
11. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):